Endomag was created by Professor Quentin Pankhurst and Simon Hattersley from UCL, in collaboration with Professor Audrius Brazdeikis at the University of Houston and UCL Business (UCL's commercialisation company). It is based on a simple research idea: to use magnetic-based sensing to replace the need for radioactivity-based approaches to determine whether breast cancer has spread from the primary tumour site into the lymphatic system, which is an important staging decision in the treatment of the disease.
The magnetic injectable and complimentary sensing device developed by the company allows pinpoint precision in locating the lymph nodes and importantly is much easier for hospitals to access than radioactive solutions – which enables patients to be treated outside of the traditional large city hospital locations.
Endomag products are now routinely used by over 1,000 hospitals in more than 45 countries. Over 500,000 women have now benefited from more precise diagnosis and less invasive breast cancer treatment.
A clear focus on clinical impact has helped the company to grow from an academic research project into a global company, says Endomag Chief Executive Dr Eric Mayes.
“Our mission at Endomag is all about helping clinicians to solve their challenges. We’re proud to be playing a part in developing products that improve outcomes and experiences for cancer patients around the world.”
In July 2024 Endomag was acquired by Hologic Inc., a U.S medical technology company primarily focused on women's health which sells medical devices for diagnostics, surgery, and medical imaging.
